Latest From OrphoMed Inc.
Appointments: Oculis, PellePharm, Syntimmune, Sterna Biologicals, Proclara Biosciences, Denovo Biopharma and OrphoMed
The latest biopharma industry appointments include new CEOs at Oculis, PellePharm, Syntimmune and Sterna Biologicals and a new CFO at Oculis, as well as new CMOs at Proclara Biosciences, Denovo Biopharma and OrphoMed.
Iterum Therapeutics and Genoa Pharmaceuticals topped the list of biopharmaceutical start-up firms closing new venture capital rounds in May with $65m and $62m, respectively, to advance drug candidates for bacterial infections and idiopathic pulmonary fibrosis.
Bicycle closes a $52m Series B to test its bicyclic peptides in humans, while Decipera, Harpoon and TP Therapeutics also top a $263m list of recent venture capital deals. In public company financings, Alnylam, Aerie and others price offerings to raise cash while their stocks are on the rise.
- Therapeutic Areas
- Hepatic (Liver)
- North America
- Company Type
- Parent & Subsidiaries
- OrphoMed Inc.
- Senior Management
Nikhilesh Singh, PhD, Pres. & CEO
Gail McIntyre, PhD, SVP, R&D
Gregory L Beyer, VP, Fin.
- Contact Info
Phone: (415) 569-4417
806 Denise Ct.
Mill Valley, CA 94941
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.